<DOC>
	<DOC>NCT01106508</DOC>
	<brief_summary>This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma or locally advanced or metastatic basal cell carcinoma) Protocol defined laboratory parameters Performance status â‰¤ 2 Patients must have fully recovered from the prior effects of major surgery and from any acute toxicities of prior chemotherapy/radiotherapy History of central nervous system tumors of symptomatic brain metastases (excludes medulloblastoma patients) Impairment of gastrointestinal function or unresolved nausea, vomiting or diarrhea Impairment of cardiac function or significant cardiac disease Pregnant or lactating women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Advanced solid tumors</keyword>
	<keyword>recurrent or refractory medulloblastoma</keyword>
	<keyword>locally advanced or metastatic basal cell carcinoma</keyword>
	<keyword>hedgehog pathway inhibitor</keyword>
</DOC>